NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I believe that over time you'll find that most trials for deadly diseases use historical data for comparison and give the experimental drug to all. The PIP is designed that way and I feel certain that new trials for DCVax-Direct will be, as well as any new trials using DCVax-L.

It's very different for therapeutics targeting more minor ailments, but in potentially terminal diseases like most cancers sufficient historical data exists to allow comparison and placebos have very little long term effects. Whether the goal is PFS or OS all should get the experimental therapeutic, hopefully better technics will be found that differentiate between progression and pseudoprogression for PFS based trials.

Gary